These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 30219151)

  • 21. Transcatheter closure of patent foramen ovale for secondary prevention of ischemic stroke: Quantitative synthesis of pooled randomized trial data.
    Hakeem A; Cilingiroglu M; Katramados A; Boudoulas KD; Iliescu C; Gundogdu B; Marmagkiolis K
    Catheter Cardiovasc Interv; 2018 Nov; 92(6):1153-1160. PubMed ID: 29332308
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patent foramen ovale closure versus medical therapy for prevention of recurrent cryptogenic embolism: updated meta-analysis of randomized clinical trials.
    Alushi B; Lauten A; Cassese S; Colleran R; Schüpke S; Rai H; Schunkert H; Meier B; Landmesser U; Kastrati A
    Clin Res Cardiol; 2018 Sep; 107(9):788-798. PubMed ID: 29644412
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke.
    Mas JL; Derumeaux G; Guillon B; Massardier E; Hosseini H; Mechtouff L; Arquizan C; Béjot Y; Vuillier F; Detante O; Guidoux C; Canaple S; Vaduva C; Dequatre-Ponchelle N; Sibon I; Garnier P; Ferrier A; Timsit S; Robinet-Borgomano E; Sablot D; Lacour JC; Zuber M; Favrole P; Pinel JF; Apoil M; Reiner P; Lefebvre C; Guérin P; Piot C; Rossi R; Dubois-Randé JL; Eicher JC; Meneveau N; Lusson JR; Bertrand B; Schleich JM; Godart F; Thambo JB; Leborgne L; Michel P; Pierard L; Turc G; Barthelet M; Charles-Nelson A; Weimar C; Moulin T; Juliard JM; Chatellier G;
    N Engl J Med; 2017 Sep; 377(11):1011-1021. PubMed ID: 28902593
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of recurrent cerebrovascular events in patients with cryptogenic stroke or transient ischemic attack and patent foramen ovale: the FORI (Foramen Ovale Registro Italiano) study.
    Paciaroni M; Agnelli G; Bertolini A; Pezzini A; Padovani A; Caso V; Venti M; Alberti A; Palmiero RA; Cerrato P; Silvestrelli G; Lanari A; Previdi P; Corea F; Balducci A; Ferri R; Falcinelli F; Filippucci E; Chiocchi P; Grandi FC; Ferigo L; Musolino R; Bersano A; Ghione I; Sacco S; Carolei A; Baldi A; Ageno W;
    Cerebrovasc Dis; 2011; 31(2):109-16. PubMed ID: 21088390
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke.
    Søndergaard L; Kasner SE; Rhodes JF; Andersen G; Iversen HK; Nielsen-Kudsk JE; Settergren M; Sjöstrand C; Roine RO; Hildick-Smith D; Spence JD; Thomassen L;
    N Engl J Med; 2017 Sep; 377(11):1033-1042. PubMed ID: 28902580
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patent Foramen Ovale and Cryptogenic Stroke or Transient Ischemic Attack: To Close or Not to Close? A Systematic Review and Meta-Analysis.
    Lattanzi S; Brigo F; Cagnetti C; Di Napoli M; Silvestrini M
    Cerebrovasc Dis; 2018; 45(5-6):193-203. PubMed ID: 29649819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PFO closure vs. medical therapy in cryptogenic stroke or transient ischemic attack: a systematic review and meta-analysis.
    Ntaios G; Papavasileiou V; Makaritsis K; Michel P
    Int J Cardiol; 2013 Oct; 169(2):101-5. PubMed ID: 24041984
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Transcatheter closure of patent foramen ovale in patients with cryptogenic stroke].
    Donti A; Egidy Assenza G; Mariucci E
    G Ital Cardiol (Rome); 2019 Feb; 20(2):73-84. PubMed ID: 30747923
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Net clinical benefit of patent foramen ovale closure in patients with cryptogenic stroke: Meta-analysis and meta-regression of randomized trials.
    Pasceri V; Pelliccia F; Bressi E; Mantione L; Gaudio C; Speciale G; Mehran R; Dangas GD; Patti G
    Int J Cardiol; 2018 Sep; 266():75-80. PubMed ID: 29887476
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Closure of patent foramen ovale or medical therapy alone for secondary prevention of cryptogenic cerebrovascular events.
    Fortuni F; Crimi G; Leonardi S; Angelini F; Raisaro A; Lanzarini LF; Oltrona Visconti L; Ferrario M; De Ferrari GM
    J Cardiovasc Med (Hagerstown); 2018 Jul; 19(7):373-381. PubMed ID: 29708911
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cryptogenic Stroke and High-Risk Patent Foramen Ovale: The DEFENSE-PFO Trial.
    Lee PH; Song JK; Kim JS; Heo R; Lee S; Kim DH; Song JM; Kang DH; Kwon SU; Kang DW; Lee D; Kwon HS; Yun SC; Sun BJ; Park JH; Lee JH; Jeong HS; Song HJ; Kim J; Park SJ
    J Am Coll Cardiol; 2018 May; 71(20):2335-2342. PubMed ID: 29544871
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Percutaneous closure of patent foramen ovale in patients with cryptogenic embolism: a network meta-analysis.
    Stortecky S; da Costa BR; Mattle HP; Carroll J; Hornung M; Sievert H; Trelle S; Windecker S; Meier B; Jüni P
    Eur Heart J; 2015 Jan; 36(2):120-8. PubMed ID: 25112661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Closure versus Medical Therapy for Patent Foramen Ovale in Patients with Cryptogenic Stroke: An Updated Meta-Analysis of Randomized Controlled Trials.
    Qiu B; Cai Y; Wang D; Lin J; Fan Y
    J Stroke Cerebrovasc Dis; 2018 Dec; 27(12):3463-3472. PubMed ID: 30185398
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patent foramen ovale closure versus medical therapy for cryptogenic stroke: An updated meta-analysis.
    Xu HB; Zhang H; Qin Y; Xue F; Xiong G; Yang L; Bai H; Wu J
    J Neurol Sci; 2018 Jul; 390():139-149. PubMed ID: 29801875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patent foramen ovale closure versus medical therapy after cryptogenic stroke: An updated meta-analysis of all randomized clinical trials.
    Kheiri B; Abdalla A; Osman M; Ahmed S; Hassan M; Bachuwa G
    Cardiol J; 2019; 26(1):47-55. PubMed ID: 29512097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Percutaneous closure of patent foramen ovale vs. medical treatment for patients with history of cryptogenic stroke: A systematic review and meta-analysis of randomized controlled trials.
    Palaiodimos L; Kokkinidis DG; Faillace RT; Foley TR; Dangas GD; Price MJ; Mastoris I
    Cardiovasc Revasc Med; 2018; 19(7 Pt B):852-858. PubMed ID: 29576519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is Patent Foramen Ovale Closure More Effective Than Medical Therapy in Preventing Stroke Recurrence in Patients With Cryptogenic Stroke?: A Critically Appraised Topic.
    Valencia-Sanchez C; Fortuin FD; Sweeney JP; Ingall TJ; Marks LA; Wingerchuk DM; O'Carroll CB
    Neurologist; 2018 Sep; 23(5):175-180. PubMed ID: 30169372
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is transcatheter closure better than medical therapy for cryptogenic stroke with patent foramen ovale? A meta-analysis of randomised trials.
    Nagaraja V; Raval J; Eslick GD; Burgess D; Denniss AR
    Heart Lung Circ; 2013 Nov; 22(11):903-9. PubMed ID: 24035325
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patent foramen ovale closure with GORE HELEX or CARDIOFORM Septal Occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: Design of the randomized Gore REDUCE Clinical Study.
    Kasner SE; Thomassen L; Søndergaard L; Rhodes JF; Larsen CC; Jacobson J
    Int J Stroke; 2017 Dec; 12(9):998-1004. PubMed ID: 29090661
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patent foramen ovale closure vs medical therapy for stroke prevention: meta-analysis of randomized trials and review of heterogeneity in meta-analyses.
    Udell JA; Opotowsky AR; Khairy P; Silversides CK; Gladstone DJ; O'Gara PT; Landzberg MJ
    Can J Cardiol; 2014 Oct; 30(10):1216-24. PubMed ID: 25154803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.